Spasticity is a common problem following spinal cord injury. The drug of choice to control spasms is baclofen. There would appear to be no reported studies which have evaluated the psychological and emotional effect of this drug. This preliminary study investigated a number of such effects, including depression, anxiety and general mood state. First, we examined 10 subjects before and during the administration of baclofen. They were then compared to a control group of 12 subjects. A second cohort of 12 subjects taking baclofen were compared to a control group of nine subjects at a specific time after injury. Results indicated that whilst some significant differences were found, suggesting an increase in fatigue with use of baclofen, no major adverse psychological effects were noted. The implications of these results were discussed and suggestions for further research were highlighted.
Introduction
For years, oral baclofen has been one of the main drugs for the treatment of spasticity after spinal cord injury. It is usually well tolerated, but with common adverse side effects such as sedation, confusion and fatigue. There have also been case reports of temporary side effects induced by baclo fen, such as frontal lobe syndrome, I psy chotic depression,2 and pseudopsychosis. 3 The reported incidence of side effects has ranged from 30% 4 to 75% .5 Gradual with drawal is usually recommended as rapid withdrawal may induce adverse effects such as visual hallucinations. 6 Despite baclofen being one of the most widely used drugs controlling spasticity, the authors can find no reference in the literature concerning the evaluation of emo tional and psychological side effects of its user. Previously, these effects have merely been clinically reported. This initial pilot study investigates the relationship between the use of baclofen and the disturbance in emotional and psychological measures.
The study attempts to do this in three ways. First, by within-subject comparison of ratings taken before and during the use of oral baclofen. Secondly, by a between subject comparison of ratings at a fixed point in time after injury of a group of subjects taking baclofen at that time and a control group who used no antispasticity medication at any time in their rehabilita tion. Finally, the study investigates whether there is any correlation between dosage of baclofen and disturbance in psychological and emotional measures. Two groups of inpatients were compared at 30 weeks post injury; one taking baclofen at that time, the other known not to have taken any antispasticity medication at any time during rehabilitation. The group taking baclofen at 30 weeks post injury consisted of the 10 patients in the experimental group described above, plus two further patients, one tetraplegic and one paraplegic (these had not been included in the original experi mental group because the data for before taking baclofen is not available for them). The comparison 2 control group was chosen so as to match for age and comprised five males and four females, average age 29 years, (SD = 8), range 19-45. It included one incomplete tetraplegic, two complete tetraplegic patients and six complete para plegics.
Measures
Depression was measured using the Beck Depression Inventory, 7 in which subjects have to choose for each item the most appropriate of four concerning their well being for the previous week. The 21 ques tions measure both somatic symptoms (eg appetite, insomnia, fatigue) and nonsomatic symptoms (eg guilt, dissatisfaction, sadness) of depression. Each item is scored 0-3, higher scores indicating more depressive symptoms.
Hopelessness was measured with the Beck Hopelessness Scale.s Subjects indicate whether their attitude toward the future, Paraplegia 32 (1994) [349] [350] [351] [352] [353] over the past week, matches that of each of the 20 statements in the scale.
Anxiety was measured using the State Anxiety Inventory (Form y).9 This consists of 20 statements concerning both anxiety, present states (eg 'I am worried'), and anxiety absent states (eg 'I feel calm'). The subjects indicate their agreement with each item at that moment. Each item is scored 1-4, higher scores indicating higher anxiety.
The Psychosocial Adjustment to Illness Scale Seven: Psychological DistresslO was used to measure dysphoric thoughts and feelings that are associated with the sub ject's disorder, or are a direct result of the illness and its sequelae. Its seven items investigate anxiety, depression, hostility, reduced self esteem, body image problems and inappropriate guilt and refer to the preceding month. Each item is scored 0-3, higher scores indicating higher distress.
The Intrusion Scale of the Impact of Events Scalell was used to measure the frequency of intrusive thoughts and images, troubled dreams, strong pangs or waves of feelings, and repetitive behaviour in the preceding week. Each of the seven items is scored 0-5, higher scores indicating higher distress.
The Profile of Mood States12 measured affect by subjects indicating the extent to which they felt their mood corresponded to the list of adjectives presented. The scales of anger, vigour, fatigue and confusion were measured by 12 and these were not elev ated, eight, seven and seven items respect ively. Each item is scored 0-4, higher score indicating higher level of that emotion.
Procedure
The subjects of this study form a subset of a larger longitudinal study currently in pro gress. The patients are rated every 6 weeks from admission to discharge on each of the psychological impact measures with a re search psychologist. This assessment takes approximately 30 minutes. The available medical records of these patients were investigated to study whether they had at any time been taking baclofen or any other antispasticity medication. This was done after all the impact measure had been taken. Hence, the rating had been taken 'blind'. 
Results
Com p arison 1: Using inde p endent t tests, no significant differences were found in any of the measures between the baclofen grou p before they started using the drug and the control grou p , or between the p re-baclofen scores and during baclofen scores in the baclofen grou p . Pearson p roduct-moment correlations were calculated with the dos ages of baclofen being taken at the time of testing and the emotional and p sychological measures. None of the correlations were significant. Com p arison 2: Inde p endent t tests were carried out to com p are the scores at 30 weeks p ost injury for those taking baclofen at that time and those who had not taken any antis p asticity at any time in their rehabi litation. Significant differences were found in two measures. Those not taking any antis p asticity medication were significantly more vigorous than those on baclofen, as measured on the POMS (t = 2.38, p < 0. 05). Corres p ondingly, those p atients taking baclofen were significantly more fatigued than those not on any antis p asticity medication as measured on the POMS (t = 2. 57, P < 0. 05). The full results are p resented in Table I .
However, these two grou p s differed greatly with res p ect to severity of injury. The grou p taking baclofen contained p ro p ortionally more tetra p legics who might be ex p ected to have lower vigour and higher fatigue than p ara p legics. In order to investi gate this, the two grou p s were colla p sed across drug use and the scores for p ara p legics and tetra p legics were com p ared. No significant differences were found on any of the measures. 
Discussion
Significant differences were found on measures of vigour and fatigue between those taking baclofen and those who took no antis p asticity medication at any time in their rehabilitation, as measured by the POMS at 30 weeks p ost injury.
This result can be challenged in two main ways. First, the no medication grou p con sisted of three tetra p legics and six p ara p le gics as com p ared to seven tetra p legics and five p ara p legics in the baclofen grou p .
Para p legics might be ex p ected to be more active and less tired than tetra p legics, which would ex p lain the observed differences. However, when the p atients were colla p sed across drug use and com p ared by severity of injury, no significant differences were found between p ara p legics and tetra p legics. Para p legics, in fact, showed slightly more fatigue. Secondly, it could be claimed that those p atients who take baclofen form a distinct grou p and there would be differ ences between them and the remaining s p inal cord injured p o p ulation, even before they started using the drug. This can be discounted by the lack of significant differ ences found in com p arison 1, between the scores of the baclofen-taking grou p before they used baclofen and those of the matched control grou p . Thus it seems that the difference in vigour and fatigue are not merely ex p erimental artefacts but due to the use of baclofen. This is consistent with clinical evidence that drowsiness is the most common adverse effect associated with the use of the drug.
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However, the within -subject design study failed to detect any significant differences between the scores of p atients taking ba clofen and those not taking baclofen. There was a trend, though, for the patients to be more fatigued and confused, and less vigor ous whilst taking the drug. The failure to find significant differences may result from the small number of subjects and large variances in the measures used. This is similarly true of the failure to find any significant correlations between dosages and the measures used. Of the measures, vigour and fatigue showed the highest correlations with dosage. An area for further study that is indicated by these results is whether baclofen affects the cognitive functioning of patients. If cognitive functioning is significantly altered this will have im p lications for rehabilitation, goal p lanning and integration. This study has highlighted the im p act on emotional wellbeing of the use of oral baclofen. Further studies would be needed to ex p lore the im p act of cognitive functioning of the use of oral baclofen. Furthermore, future studies would need to include large subject numbers to increase the p ower of the analysis and the adoption of a within-subject design that would p rovide the most direct evidence of the effects of the use of oral baclofen.
